Dendritic Cell-Based Immunotherapy in Lung Cancer

Lung cancer remains the leading cause of cancer-related death worldwide. The advent immune checkpoint inhibitors has led to a paradigm shift in treatment metastatic non-small cell and small lung cancer. However, despite prolonged overall survival, only minority patients derive clinical benefit from these treatments suggesting that full anti-tumoral potential system is not being harnessed yet. One way overcome this problem combine blockade with different strategies aimed at inducing or restoring cellular immunity tumor-specific, robust, durable way. Owing their unique capacity initiate regulate T responses, dendritic cells have been extensively explored as tools for immunotherapy many tumors, including In review, we provide an update on nearly twenty years experience cell-based We summarize main results early phase trials give overview future perspectives within field.